文献速递浆细胞疾病

miR-202通过激活JNK/SAPK信号通路显著增强MM细胞对药物的敏感性

[miR-202 contributes to sensitizing MM cells to drug significantly via activing JNK/SAPK signaling pathway].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2016-01-01

研究检测了miR-202及其靶基因BAFF在多发性骨髓瘤(MM)细胞中的表达,并通过转染U266细胞观察其对增殖、凋亡及药物敏感性的影响。结果显示MM细胞中miR-202低表达、BAFF高表达,miR-202模拟物联合硼替佐米可协同抑制增殖并诱导凋亡,其机制可能涉及负向调控BAFF并抑制JNK/SAPK通路。

要点

  • MM患者CD138+细胞及U266细胞中miR-202表达低于健康对照,BAFF表达高于健康对照。
  • miR-202模拟物转染可抑制U266细胞增殖并诱导凋亡。
  • miR-202模拟物联合硼替佐米较单用硼替佐米进一步提高凋亡率与增殖抑制率。

核心结论

  • miR-202模拟物联合硼替佐米可抑制U266细胞增殖并诱导凋亡,可能通过负向调控靶基因BAFF、进而抑制JNK/SAPK信号通路活化实现。

研究设计与样本

  • 实验研究:荧光定量PCR检测miR-202及BAFF mRNA水平,将miR-202模拟物、miR-202抑制物、siBAFF及其阴性对照转染U266细胞,Western blot检测Bcl-2家族和MAPK信号通路蛋白,WST-1法和Annexin V-FLUOS流式细胞术分别检测增殖和凋亡。

主要发现

  • U266细胞miR-202表达为0.052±0.009、MM患者CD138+细胞为0.304±0.354,均低于健康对照的3.550±1.126(P<0.001,P=0.009)。
  • U266细胞BAFF mRNA水平为5.700±0.734、MM患者CD138+细胞为9.576±2.887,均高于健康对照的1.819±0.853(P<0.001,P=0.006)。
  • miR-202模拟物转染组U266细胞增殖抑制率为(56.04±0.02)%,高于对照组的(18.89±0.32)%(P=0.002)。
  • 转染miR-202模拟物后U266细胞Bcl-2表达下调约24%,Bax蛋白表达上调约1.24倍。
  • miR-202模拟物组细胞凋亡率为(49.60±4.89)%,高于对照组的(26.20±1.28)%(P=0.029)。

关键数值与推荐

  • 硼替佐米联合miR-202模拟物组细胞凋亡率为(51.23±5.41)%,高于硼替佐米单独处理组的(31.70±4.40)%(P=0.047),也高于硼替佐米与模拟物对照联合处理组的(27.94±4.04)%(P=0.028)。
  • miR-202模拟物联合沙利度胺与miR-202模拟物对照组凋亡率分别为(11.66±1.91)%与(10.63±1.74)%,差异无统计学意义(P=0.700)。
  • miR-202模拟物联合地塞米松与miR-202模拟物对照组凋亡率分别为(16.35±1.32)%与(17.43±1.95)%,差异无统计学意义(P=0.400)。
  • miR-202模拟物联合硼替佐米组U266细胞增殖抑制率为(36.93±5.98)%,高于硼替佐米单独处理组的(18.18±4.10)%(P=0.029)。
  • miR-202模拟物及硼替佐米处理U266细胞后p-JNK蛋白表达水平下调。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the role of miR-202 in multiple myeloma (MM) cells, and study the regulation of miR-202 on drug sensitivity of MM cells. Methods: miR-202 and BAFF mRNA levels were detected by real-time PCR. U266 cells were transfected with miR-202-mimics, miR-202-inhibitor, siBAFF and their negative controls. After above treatments, protein levels of Bcl-2 family and MAPK signaling pathway were detected by Western blot analysis, and the proliferation and apoptosis ability of MM cells were examined by WST-1, Annexin V-FLUOS assay, respectively. Results: The results showed that the expression of miR-202 in CD138+ MM cells (0.304±0.354) and U266 cells (0.052± 0.009) were lower than in normal controls (3.550 ± 1.126) (P<0.001, P=0.009), whereas BAFF mRNA levels (5.700 ± 0.734, 9.576 ± 2.887) were higher than in normal controls (1.819 ± 0.853) (P<0.001, P= 0.006). The proliferation ability of U266 cells transfected with miR-202 mimics was significantly inhibited than in control group [(56.04±0.021)% vs (18.89±0.32)%, P=0.002]. The result of Western blot showed that the expression of Bcl-2 decreased by about 24%, and the expression of Bax increased by about 124% in cells transfected with miR-202 mimics. The apoptosis rate in cells transfected with miR-202 mimics was significantly more than in control group [(49.60±4.89)% vs (26.20±1.28)%, P=0.029]. The apoptosis rate in miR-202 mimics combined with Bort group (51.23±5.41)% was higher as compared with Bort treatment alone (31.70±4.40)% or miR-202 mimics control combined with Bort group (27.94±4.04)%, (P=0.047, P= 0.028), whereas the apoptosis rate in miR-202 mimics combined with Thal or Dex had no significant difference compared with miR-202 mimics control [(11.66±1.91)% vs (10.63±1.74)%, P=0.700; (16.35± 1.32)% vs (17.43 ± 1.95)%, P=0.400]. The inhibitory rate of cell growth in miR-202 mimics combined with Bort group was higher as compared with Bort treatment alone [(36.93±5.98)% vs (18.18±4.10)%, P= 0.029]. The expressions of p-JNK protein decreased in U266 cells transfected with miR-202 mimics and treated with Bort. Conclusion: miR-202 mimics combined with Bort could inhibit proliferation and induce apoptosis of U266 cells through negative regulating target gene BAFF, which further inhibited the JNK/SAPK signaling pathway. 目的: 研究microRNA-202(miR-202)对多发性骨髓瘤(MM)细胞生长的影响,并初步探讨miR-202在MM细胞药物敏感性中的作用机制。 方法: 荧光定量PCR检测miR-202及其靶基因B淋巴细胞刺激因子(BAFF)在MM细胞中的表达水平。将miR-202模拟物、miR-202抑制物、BAFF干扰质粒(siBAFF)及其阴性对照转染U266细胞,Western blot检测Bcl-2家族和MAPK信号通路蛋白的表达。WST-1法、流式细胞术(Annexin V-FLUOS)分别检测转染后U266细胞的增殖和凋亡情况。 结果: U266细胞、MM患者CD138+细胞中miR-202 mRNA表达(分别为0.052±0.009、0.304±0.354)均低于健康对照组(3.550±1.126)(P<0.001,P=0.009),BAFF表达水平(5.700±0.734、9.576±2.887)均高于健康对照组(1.819±0.853)(P<0.001,P=0.006)。miR-202模拟物转染组细胞增殖抑制率高于对照组[(56.04±0.02)%对(18.89±0.32)%,P=0.002]。Western blot结果显示,转染miR-202模拟物后,U266细胞Bcl-2表达下调约24%,而Bax蛋白的表达上调约1.24倍,miR-202模拟物组细胞凋亡率高于对照组[(49.60 ± 4.89)%对(26.20 ± 1.28)%,P=0.029]。硼替佐米和miR-202模拟物联合组细胞凋亡率为(51.23 ± 5.41)%,高于硼替佐米单独处理组(31.70 ± 4.40)%和硼替佐米与模拟物对照联合处理组[(51.23±5.41)%对(31.70±4.40)%,P=0.047;(51.23±5.41)%对(27.94±4.04)%,P=0.028)],而miR-202模拟物联合沙利度胺和地塞米松与miR-202模拟物对照组相比差异无统计学意义[(11.66±1.91)%对(10.63±1.74)%,P=0.700;(16.35±1.32)%对(17.43±1.95)%,P=0.400]。miR-202模拟物联合硼替佐米对U266细胞的增殖抑制率高于硼替佐米单独处理组[(36.93±5.98)%对(18.18±4.10)%,P=0.029]。miR-202模拟物及硼替佐米处理U266细胞后,p-JNK蛋白表达水平下调。 结论: miR-202模拟物和硼替佐米可协同抑制MM细胞增殖、诱导其凋亡,可能通过miR-202负向调控靶基因BAFF的表达、抑制JNK/SAPK信号通路的活化来实现的。

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Shen XJ, Wu XH, et al. [miR-202 contributes to sensitizing MM cells to drug significantly via activing JNK/SAPK signaling pathway]. Zhonghua Xue Ye Xue Za Zhi. 2016. PMID: 27995886. doi:10.3760/cma.j.issn.0253-2727.2016.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。